GABRP Antibody

What is GABRP and why is it a significant research target?

GABRP is a transmembrane protein belonging to the GABA(A) receptors family. Unlike other GABA(A) subunits that are abundant in the brain, GABRP is detectable in multiple non-neuronal tissues, including mammary gland, prostate gland, lung, thymus, and uterus . Its significance as a research target stems from its:

• Overexpression in multiple cancer types, particularly triple-negative breast cancer (TNBC)

• Role in pancreatic adenocarcinoma (PAAD) progression

• Involvement in airway epithelial cell differentiation in asthma

• Potential as a novel therapeutic target for antibody-drug conjugate (ADC) development

GABRP has been identified as a membrane-localized protein with a range of 815-53,714 receptors per cell in various cancer cell lines, making it an accessible target for antibody-based interventions .

What methodologies are commonly used to detect GABRP expression?

Several complementary techniques are employed to comprehensively assess GABRP expression:

• RT-qPCR: For mRNA quantification, validated primers include GABRP (Hs00959454_m1)

• Western Blot: Using antibodies targeting either the intracellular domain (ICD) or extracellular domain (ECD)

• Immunohistochemistry (IHC): For protein expression in tissue samples, useful for clinical correlation studies

• Flow Cytometry: For cell surface quantification, particularly using QuantiBRITE PE assay to determine receptor density

• Transcriptome Analysis: For comparing GABRP expression across different cell populations

Combined methodologies provide more robust verification of expression patterns, as occasionally substantial discordance between mRNA and protein levels has been documented .

Which cell lines are recommended for GABRP research?

Based on the literature, the following cell lines show significant GABRP expression:

TNBC cell lines with high GABRP expression:

• HCC1143

• MDA-MB-468

• HCC70

TNBC cell lines with low GABRP expression:

• MDA-MB-231

Other breast cancer cell lines with detectable GABRP:

• SKBR3 (HER2+)

• BT-474 (Luminal)

For airway research, mouse Club cells show high GABRP expression compared to alveolar type 2 (AT2) cells, with a fold change of 55.3 as confirmed by microarray analysis .

What are key considerations for selecting GABRP antibodies?

When selecting GABRP antibodies for research, consider:

• Target Domain: Antibodies targeting the extracellular domain (ECD) versus intracellular domain (ICD) have different applications. ECD-binding antibodies can be used for functional studies and ADC development

• Validation Status: Confirm validation in your application of interest (WB, IHC, FACS, etc.)

• Species Reactivity: Available antibodies may react with human, mouse, rat, dog, and other species

• Clonality: Polyclonal antibodies offer broader epitope recognition, while monoclonal antibodies provide higher specificity

• Storage Conditions: Typically stored at -20°C in PBS with sodium azide and glycerol

For functional studies, evidence suggests that ECD-binding antibodies show growth inhibitory effects at concentrations from 5-100 μg/ml, while ICD-binding antibodies do not exhibit this effect .

What methodological approaches are recommended for investigating GABRP function in cancer progression?

To robustly investigate GABRP function in cancer, a multi-modal approach is recommended:

Gene Silencing Methods:

• siRNA knockdown: Effective for short-term studies showing modest but significant suppression of growth in high-GABRP TNBC cell lines (HCC1143 and MDA-MB-468)

• CRISPR/Cas9 knockout: Preferred for stable knockout models, though achieving complete GABRP KO in polyclones can be challenging (55% decrease in protein level was achieved in MDA-MB-468 cells)

• shRNA: Used successfully to suppress growth of MDA-MB-468 xenografts in nude mice

Functional Assays:

• Colony formation assays: For assessing tumorigenic potential in vitro

• Migration assays: To evaluate metastatic potential

• Organoid culture systems: Particularly useful for airway epithelial studies, incorporating specific inhibitors like bicuculline methiodide (BMI)

• Xenograft models: For in vivo verification of findings

Signaling Pathway Analysis:

• Western blot analysis: To monitor downstream effects on pathways like ERK1/2

• Gene set enrichment analysis (GSEA): To explore molecular mechanisms broadly

These complementary approaches provide more comprehensive insights than single-method studies and help validate findings across different experimental systems.

How is GABRP involved in immune response and what methods can assess this relationship?

GABRP appears to play important roles in immune response, particularly in pancreatic cancer. To investigate this relationship:

Computational Methods:

• GSEA analysis: Reveals GABRP's role in immune response pathways

• TIMER database: Explores correlations between GABRP expression and immune cell infiltration

• CIBERSORT algorithm: Quantifies immune cell type abundances from gene expression profiles

• ESTIMATE algorithm: Predicts tumor purity and presence of infiltrating stromal/immune cells

Experimental Approaches:

• Multiplex immunofluorescence: To visualize spatial relationships between GABRP-expressing cells and immune cell populations

• Cytokine profiling: To assess impacts on inflammatory mediators

• Immune cell co-culture systems: To evaluate direct effects on immune cell function

When designing studies, researchers should consider both innate and adaptive immune components, as GABRP may influence multiple aspects of tumor immunity through mechanisms that remain incompletely characterized.

What are the methodological considerations for developing GABRP-targeted antibody-drug conjugates (ADCs)?

Development of GABRP-targeted ADCs requires careful optimization of multiple parameters:

Target Validation Considerations:

• Receptor density quantification: Mean receptor numbers between 2,800-6,194 per cell are within the range of clinically useful ADCs (comparable to CD22: 4,695; CD33: 1,000-10,000)

• Internalization dynamics: Critical for ADC efficacy but requires further characterization for GABRP

• Expression in normal tissues: Low expression in most normal tissues suggests favorable therapeutic index

Antibody Selection Criteria:

• Epitope specificity: Target accessible epitopes on the extracellular domain

• Binding affinity: Optimize for efficient internalization

• Species cross-reactivity: Important for preclinical toxicology studies

Conjugation Optimization:

• Toxin selection: Initial studies with DM1 (mertansine) show promising results

• Drug-to-antibody ratio (DAR): Higher than 3-4 DM1 molecules per antibody can reduce antigen-binding potency, solubility, and stability

• Linker chemistry: Affects stability and release kinetics

Validation Methods:

• In vitro cytotoxicity: Test in isogenic cell lines with varying GABRP expression levels

• Specificity controls: Use GABRP CRISPR KO cells to confirm specific activity

• Bystander effect evaluation: Important for heterogeneous tumor targeting

Preliminary research using anti-GABRP-DM1 conjugates demonstrated significant growth inhibition at nanomolar concentrations (10-500 nM) compared to control IgG-DM1 conjugates, providing proof-of-concept for further optimization .

What are the differences in GABRP function between different disease contexts, and how should research approaches be adapted?

GABRP appears to play context-dependent roles across different pathologies, requiring tailored research approaches:

Triple-Negative Breast Cancer (TNBC):

• Function: Promotes cell migration, tumorigenic potential, and potentially brain metastasis

• Research Focus: Cytoskeletal alterations, basal-like cytokeratin expression (KRT5, KRT6B, KRT14, KRT17), and ERK1/2 signaling

• Methods: Focus on migration assays, secondary tumorsphere formation, and brain metastasis models

Pancreatic Adenocarcinoma (PAAD):

• Function: Associated with immune response and potential prognostic biomarker

• Research Focus: Immune infiltration correlations and survival analysis

• Methods: Kaplan-Meier analysis, GSEA, and immune infiltration assessment using TIMER and CIBERSORT

Bronchial Asthma:

• Function: Essential for Club cell proliferation and differentiation into goblet cells

• Research Focus: Mucin production (Muc5Ac, Muc5B) and epithelial differentiation

• Methods: Organoid cultures, naphthalene-induced Club cell injury models, and RT-qPCR for differentiation markers

Comparative Table of GABRP Function Across Diseases:

Research approaches should be adapted to these specific contexts to generate the most relevant insights into GABRP biology.

How can contradictions in GABRP expression between mRNA and protein levels be reconciled methodologically?

Researchers have observed discrepancies between GABRP mRNA and protein expression patterns, particularly in ER-positive cancers . To address these contradictions:

Methodological Approaches:

• Multi-level analysis: Always perform both mRNA and protein detection in the same samples

• Subcellular fractionation: Determine if protein localization affects detection efficiency

• Antibody validation: Use multiple antibodies targeting different epitopes to confirm specificity

• Post-translational modification assessment: Investigate if modifications affect antibody recognition

• Protein stability studies: Assess if differential protein stability explains discordance

Technical Considerations:

• Sample preparation standardization: Use consistent protocols for tissue handling

• Quantitative methods: Employ digital PCR for absolute mRNA quantification and quantitative proteomics for protein levels

• Single-cell analysis: Consider if cellular heterogeneity explains population-level discrepancies

Reporting Recommendations:

These approaches can help reconcile seemingly contradictory findings and provide a more complete understanding of GABRP biology in different contexts.

What are the current challenges in optimizing GABRP antibodies for therapeutic applications?

Several challenges remain in developing GABRP antibodies for therapeutic use:

Target-Related Challenges:

• Receptor heterogeneity: Wide range of receptor density (815-53,714 receptors/cell) requires careful consideration of targeting strategy

• Epitope accessibility: Optimal binding sites on the ECD need further characterization

• Functional redundancy: Potential compensation by other GABA receptor subtypes

Antibody Optimization Challenges:

• Internalization efficiency: Currently suboptimal for ADC applications and requires enhancement

• Conjugation uniformity: Non-uniform DM1 conjugation (varying binding to ~30 available IgG lysine sites) results in heterogeneous ADCs with variable efficacy

• Antibody formats: Need to evaluate various formats (IgG, Fab, scFv) for optimal tissue penetration and efficacy

Clinical Translation Barriers:

• Patient stratification: Need to identify biomarkers predicting response to GABRP-targeted therapies

• Combination strategies: Determine optimal combination with existing therapies

• Resistance mechanisms: Anticipate and address potential resistance pathways